Bioassay Kit
바이오의약품(biologics), 바이오시밀러, 바이오베터 연구자들을 위해 기존 바이오 의약품 및 reference ligand로 validation된 bioassay Kit
Eurofins Discovery에서는 바이오의약품(Biologics), 바이오시밀러, 바이오베터 연구자들은 위해 기존 바이오 의약품 및 reference ligand로 Validation된 Bioassay Kit를 제공합니다.
재현성이 뛰어나며, lot 별 variation이 낮아(10% 이하), 후보 바이오 의약품의 약효(potency)평가 및 lot 별 품질평가(QC)에도 사용이 가능합니다.
Figure 1. Examples of eight bioassays developed as both potency and neutralizing antibody (NAb) assays for biosimilars; (A) response to three commercial insulin therapeutics (Humalog, Novolog, and Lantus) in a cellbased functional assay that measures activation of human insulin receptor; (B) a GLP1 and Exendin-4 bioassay was developed to accelerate development of biosimilars to metabolic drugs using a cyclic AMP readout in live cells. (C) A bioassay developed for anti-TNFα drugs enables users to benchmark drugs such as adalimumab,
infliximab, etanercept, golimumab, and certolizumab against their respective biosimilar molecules. (D) A simple assay determines potency of the anti-inflammatory antibody ustekinumab.
Qualified Bioassay Kit
오리지널 바이오 의약품으로 Validation 된 Bioassay Kit
| INN Drug Name | Qualified With | Molecular MOA | Assay Measures | Bioassay Kits | Configuration |
| Rituximab | – | Cytotoxicity | Antibody-Dependent Cellular-Cytotoxicity | 97-1012Y026-00169 | 2-plate |
| 97-1012Y026-00170 | 10-plate | ||||
| Semaglutide | Ozempic® | GLP1R agonist | cAMP Accumulation | 95-0062Y2-00175 | 2-plate |
| 95-0062Y2-00176 | 10-plate | ||||
| Aflibercept | Eylea® | VEGF-Trap | VEGFR2 (KDR) Dimerization | New HS Version* | |
| 93-0996Y1-00153 | 2-plate | ||||
| 93-0996Y1-00154 | 10-plate | ||||
| Standard | |||||
| 93-0996Y1-00005 | 2-plate | ||||
| 93-0996Y1-00006 | 10-plate | ||||
| Bevacizumab | Avastin® | Anti-VEGFA mAb | VEGFR2 (KDR) Dimerization | New HS Version* | |
| 93-0996Y1-00165 | 2-plate | ||||
| 93-0996Y1-00166 | 10-plate | ||||
| Standard | |||||
| 93-0996Y1-00001 | 2-plate | ||||
| 93-0996Y1-00002 | 10-plate | ||||
| Ranibizumab | Lucentis® | Anti-VEGFA mAb | VEGFR2 (KDR) Dimerization | New HS Version* | |
| 93-0996Y1-00167 | 2-plate | ||||
| 93-0996Y1-00168 | 10-plate | ||||
| Standard | |||||
| 93-0996Y1-00003 | 2-plate | ||||
| 93-0996Y1-00004 | 10-plate | ||||
| Adalimumab | Humira® | Anti-TNFα mAb | IkB Degradation | 93-0538B15-00131 | 2-plate |
| 93-0538B15-00132 | 10-plate | ||||
| Anti-PD-1/PD-L1 | Keytruda® | PD-L1-induced PD-1 signaling | SHP Recruitment | 93-1104Y19-00117 | 2-plate |
| 93-1104Y19-00118 | 10-plate | ||||
| Tocilizumab | Actemra® | Anti-ligand (IL-6) or anti-receptor (IL-6RA) drugs | Ligand-induced receptor dimerization (IL6RA/IL6ST) | 93-1045B3-00109 | 2-plate |
| 93-1045B3-00110 | 10-plate | ||||
| Anakinra | Kineret® | IL-1RA (Inhibits IL-1) | IL1R/IL1RAP Dimerization | 93-1032Y3-00105 | 2-plate |
| 93-1032Y3-00106 | 10-plate | ||||
| Darbepoetin Alfa | Aranesp® | EPOR agonist | EpoR/EpoR Dimerization | 93-0965Y3-00019 | 2-plate |
| 93-0965Y3-00020 | 10-plate | ||||
| Epoetin Alfa | Recombinant hEpo | EPOR agonist | EpoR/EpoR Dimerization | 93-0965Y3-00017 | 2-plate |
| 93-0965Y3-00018 | 10-plate | ||||
| Exenatide | Byetta® | GLP1R agonist | cAMP Accumulation | 95-0062Y2-00101 | 2-plate |
| 95-0062Y2-00102 | 10-plate | ||||
| Liraglutide | Victoza® | GLP1R agonist | cAMP Accumulation | 95-0062Y2-00099 | 2-plate |
| 95-0062Y2-00100 | 10-plate | ||||
| Insulin Glargine | USP Insulin | INSRb agonist | SH2 Recruitment | 93-0466Y3-00011 | 2-plate |
| 93-0466Y3-00012 | 10-plate | ||||
| Insulin Lispro | USP Insulin | INSRb agonist | SH2 Recruitment | 93-0466Y3-00009 | 2-plate |
| 93-0466Y3-00010 | 10-plate | ||||
| Insulin | USP Insulin | INSRb agonist | SH2 Recruitment | 93-0466Y3-00007 | 2-plate |
| 93-0466Y3-00008 | 10-plate | ||||
| Panitumumab | Vectibix® | Anti-EGFR mAb | EGFR/ErbB2 Dimerization | 93-1051Y3-00093 | 2-plate |
| 93-1051Y3-00094 | 10-plate | ||||
| Pertuzumab | Perjeta® | Anti-HER2-dimerization mAb | ErbB2/ErbB3 Dimerization | 93-1042Y3-00095 | 2-plate |
| 93-1042Y3-00096 | 10-plate | ||||
| Teriparatide | Forteo® | PTHR agonist | cAMP Accumulation | 95-0118Y2-00057 | 2-plate |
| 95-0118Y2-00058 | 10-plate | ||||
| Somatotropin, Somatropin | Recombinant hGH | GHR agonist | SH2 Recruitment | 93-0756Y3-00023 | 2-plate |
| 93-0756Y3-00024 | 10-plate | ||||
| Follitropin alfa | Gonal-F | FSHR agonist | cAMP Accumulation | 95-0119Y2-00103 | 2-plate |
| 95-0119Y2-00104 | 10-plate | ||||
| Sargramostim | Leukine® | Recombinant GM-CSF(CSFR2 agonist) | CSF2RB/CSF2R Dimerization | 93-1078Y3-00111 | 2-plate |
| 93-1078Y3-00112 | 10-plate | ||||
*HS Bioassay kits have been further optimized to deliver reproducible results with lower variability.
Target-Based Bioassay Kit
| Target | Molecular MOA | Assay Measures | Bioassay Kits | Configuration |
| IL2RB/IL2RG | IL-15 Agonist | Ligand induced receptor (IL2Rβ/IL2Rγ) dimerization | 93-0998Y3-00183 | 2-plate |
| 93-0998Y3-00184 | 10-plate | |||
| 93-0998Y3-00188 | 10-plate | |||
| (no ligand) | ||||
| HER2 | Cytotoxicity | Antibody-Dependent Cellular-Cytotoxicity | 97-1004Y021-00173 | 2-plate |
| 97-1004Y021-00174 | 10-plate | |||
| CD19, CD20, CD38 | Cytotoxicity | Antibody-Dependent Cellular-Phagocytosis | 97-1012Y026-00179 | 2-plate |
| 97-1012Y026-00180 | 10-plate | |||
| 97-1009Y025-00177 | 2-plate | |||
| 97-1009Y025-00178 | 10-plate | |||
| CD19, CD20, CD38 | Cytotoxicity | Antibody- Dependent Cellular-Cytotoxicity | 97-1012Y026-00169 | 2-plate |
| 97-1012Y026-00170 | 10-plate | |||
| 97-1009Y025-00171 | 2-plate | |||
| 97-1009Y025-00171 | 10-plate | |||
| IL7R/IL2RG | IL-7 Agonists | Ligand-induced receptor (IL7R/IL2RG) Dimerization |
93-0997Y13-00081 | 2-plate |
| 93-0997Y13-00082 | 10-plate | |||
| IL1RL1/IL1RAP | IL-33 Antagonists | Ligand-induced receptor (IL1RL1/IL1RAP) Dimerization | 93-1067Y3-00079 | 2-plate |
| 93-1067Y3-00080 | 10-plate | |||
| TrkA-p75 | Agonist drugs | SH2 Recruitment | 93-0529Y3-00147 | 2-plate |
| 93-0529Y3-00148 | 10-plate | |||
| MCHR1 | Agonist drugs | β-Arrestin Recruitment | 93-0940Y3-00149 | 2-plate |
| 93-0940Y3-00150 | 10-plate | |||
| GHSR | Agonist drugs | β-Arrestin Recruitment | 93-0242Y3-00141 | 2-plate |
| 93-0242Y3-00142 | 10-plate | |||
| LHCGR | Agonist drugs | cAMP Accumulation | 95-0106Y2-00137 | 2-plate |
| 95-0106Y2-00138 | 10-plate | |||
| MRGPRX2 | Agonist drugs | β-Arrestin Recruitment | 93-0309Y2-00143 | 2-plate |
| 93-0309Y2-00144 | 10-plate | |||
| AGTR1 | AGTR1 Agonists | β-Arrestin Recruitment | 93-0312Y2-00125 | 2-plate |
| 93-0312Y2-00126 | 10-plate | |||
| AGTRL1 | AGTRL1 Agonists | β-Arrestin Recruitment | 93-0250Y2-00121 | 2-plate |
| 93-0250Y2-00122 | 10-plate | |||
| BDKRB2 | BDKRB2 Agonists | β-Arrestin Recruitment | 93-0189Y2-00113 | 2-plate |
| 93-0189Y2-00114 | 10-plate | |||
| CNR1 | CNR1 Agonists | β-Arrestin Recruitment | 93-0959Y2-00119 | 2-plate |
| 93-0959Y2-00120 | 10-plate | |||
| C5AR1 | Anti-ligand (anti-C5a) | β-Arrestin Recruitment | 93-0557Y2-00059 | 2-plate |
| 93-0557Y2-00060 | 10-plate | |||
| CCR2 | Antagonist drugs | β-Arrestin Recruitment | 93-0192Y2-00061 | 2-plate |
| 93-0192Y2-00062 | 10-plate | |||
| CXCR5 | Antagonist drugs | β-Arrestin Recruitment | 93-0514Y2-00063 | 2-plate |
| 93-0514Y2-00064 | 10-plate | |||
| Exendin-4 | Agonist drugs | β-Arrestin Recruitment | 93-0300Y2-00029 | 2-plate |
| 93-0300Y2-00030 | 10-plate | |||
| FGFR4-β-Klotho | Agonist drugs | SH2 Recruitment | 93-1060Y3-00089 | 2-plate |
| 93-1060Y3-00090 | 10-plate | |||
| GPBAR1 | Agonist drugs | cAMP Accumulation | 95-0049Y2-00139 | 2-plate |
| 95-0049Y2-00140 | 10-plate | |||
| GLP1R | Agonist drugs | β-Arrestin Recruitment | 93-0300Y2-00027 | 2-plate |
| 93-0300Y2-00028 | 10-plate | |||
| GLP2R | Agonist drugs | β-Arrestin Recruitment | 93-0572Y2-00133 | 2-plate |
| 93-0572Y2-00134 | 10-plate | |||
| IGF1R | Agonist drugs | SH2 Recruitment | 93-0505Y1-00069 | 2-plate |
| 93-0505Y1-00070 | 10-plate | |||
| IL2RB/IL2RG/IL2RA | Modified agonists; anti-IL2 drugs | Ligand-Induced Receptor (IL2RB/IL2RG/IL2RA) Hetero-oligomerization |
93-1003Y3-00091 | 2-plate |
| 93-1003Y3-00092 | 10-plate | |||
| IL6R/IL6ST | Anti-IL-6 mAbs | Ligand-induced receptor (IL6RA/IL6ST) dimerization | 93-1045Y3-00043 | 2-plate |
| 93-1045Y3-00044 | 10-plate | |||
| IL10RA/IL10RB | anti-receptor (IL-10RA) drugs |
Ligand-induced receptor dimerization (IL10RA/IL10RB) | 93-0985Y3-00135 | 2-plate |
| 93-0985Y3-00136 | 10-plate | |||
| IL17RA/IL17RC | Anti-IL-17 mABs | Ligand-induced receptor (IL17RC/IL17RC) Dimerization | 93-0999Y3-00053 | 2-plate |
| 93-0999Y3-00054 | 10-plate | |||
| IL31RA/OSMRb | anti-ligand (IL-31); anti-receptor drugs | Ligand-induced receptor (IL31RA/OSMRb) dimerization | 93-1002Y3-00083 | 2-plate |
| 93-1002Y3-00084 | 10-plate | |||
| MC4R | Antagonist drugs | β-Arrestin Recruitment | 93-0211Y3-00085 | 2-plate |
| 93-0211Y3-00086 | 10-plate | |||
| NPY2R (β-Arrestin) | Agonist, Antagonist drugs | β-Arrestin Recruitment | 93-0212Y2-00065 | 2-plate |
| 93-0212Y2-00066 | 10-plate | |||
| NPY2R (cAMP) | Agonist, Antagonist drugs | cAMP Accumulation | 95-0077Y2-00055 | 2-plate |
| 95-0077Y2-00056 | 10-plate | |||
| PD-1 | Anti-PD-1, PD-L1 drugs | SHP Recruitment | 93-1104Y19-00117 | 2-plate |
| 93-1104Y19-00118 | 10-plate | |||
| PDGFRA | Antagonist drugs | SH2 Recruitment | 93-0823Y3-00071 | 2-plate |
| 93-0823Y3-00072 | 10-plate | |||
| PDGFRB | Antagonist drugs | SH2 Recruitment | 93-0493Y3-00073 | 2-plate |
| 93-0493Y3-00074 | 10-plate | |||
| Parathyroid Hormone(PTH) Receptor | Agonist drugs | β-Arrestin Recruitment | 93-0315Y2-00047 | 2-plate |
| 93-0315Y2-00048 | 10-plate | |||
| SIRPa (-CD47) | Agonist, Antagonist drugs | SH2 Recruitment | 93-1135Y19-00129 | 2-plate |
| 93-1135Y19-00130 | 10-plate | |||
| SSTR2 | Agonist drugs | β-Arrestin Recruitment | 93-0181Y2-00067 | 2-plate |
| 93-0181Y2-00068 | 10-plate | |||
| TrkB-p75 | Antagonist drugs | SH2 Recruitment | 93-0530Y3-00075 | 2-plate |
| 93-0530Y3-00076 | 10-plate | |||
| TrkC | Antagonist drugs | SH2 Recruitment | 93-0464Y3-00077 | 2-plate |
| 93-0464Y3-00078 | 10-plate | |||
| VIPR2 | Agonist drugs | β-Arrestin Recruitment | 93-0317Y2-00087 | 2-plate |
| 93-0317Y2-00088 | 10-plate |